Compare VHI & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHI | OCGN |
|---|---|---|
| Founded | 1932 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.5M | 387.3M |
| IPO Year | N/A | N/A |
| Metric | VHI | OCGN |
|---|---|---|
| Price | $12.58 | $1.39 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $7.00 |
| AVG Volume (30 Days) | 24.2K | ★ 3.1M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,063,400,000.00 | $5,370,000.00 |
| Revenue This Year | $22.20 | $32.40 |
| Revenue Next Year | $7.66 | N/A |
| P/E Ratio | $19.70 | ★ N/A |
| Revenue Growth | N/A | ★ 14.26 |
| 52 Week Low | $11.94 | $0.52 |
| 52 Week High | $25.25 | $1.90 |
| Indicator | VHI | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 62.21 |
| Support Level | $12.00 | $1.18 |
| Resistance Level | $12.98 | $1.26 |
| Average True Range (ATR) | 0.57 | 0.07 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 36.52 | 75.80 |
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").